We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi

Alexander C. J. van Akkooi MD, PhD

Melanoma and Soft Tissue Sarcoma Surgeon, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in melanoma and sarcoma and practicing at the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NCI-AVL) in Amsterdam. Dr van Akkooi is the current chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. He is the head of the NCI-AVL Skin Cancer and Melanoma Unit. Dr van Akkooi has published over 150 peer-reviewed papers in high-impact journals, including NEJM, Lancet, Lancet Oncology, Cell, Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology, Society for Melanoma Research, and American Society of Clinical Oncology.

Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam, and underwent residency training in surgical oncology at NCI-AVL and Erasmus MC Cancer Institute. His PhD was awarded cum laude from Erasmus University.

Disclosures

Dr. van Akkooi is on the Advisory Board of & has received Consultancy Honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi, 4SC. He also reports Research Grants from Amgen, Novartis, Merck-Pfizer which were all paid to NCI-AVL.

Recent Contributions to PracticeUpdate:

  1. Update on Tolerability and Overall Survival in COLUMBUS: Encorafenib + Binimetinib vs Vemurafenib or Encorafenib in BRAF V600–Mutant Melanoma
  2. Potential Detrimental Effect of Antibiotics on Clinical Outcomes in the Setting of Immune-Checkpoint Blockade
  3. DCE-MRI Perfusion Predicts Pseudoprogression in Metastatic Melanoma Treated With Immunotherapy
  4. The Potential Development of PD-L1 as a Biomarker in Advanced Melanoma
  5. An Open-Source Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Melanoma
  6. Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma
  7. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade
  8. Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab for Advanced Solid Tumors
  9. A Systematic Literature Review and Network Meta-Analysis of Effectiveness and Safety Outcomes in Advanced Melanoma
  10. Updates on T-VEC in the Management of Melanoma

Most Read This Week

Recently Updated